BCM
NGNE icon

Bridgeway Capital Management’s Neurogene NGNE Stock Holding History

Bridgeway Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$379K Buy
18,781
+8,000
+74% +$155K 0.01% 878
2025
Q4 		$222K Hold
10,781
– – ﹤0.01% 996
2025
Q3 		$187K Buy
+10,781
New +$217K ﹤0.01% 1027
2023
Q2 		– Sell
-3,750
Closed -$52.5K – 1427
2023
Q1 		$52.5K Hold
3,750
– – ﹤0.01% 1306
2022
Q4 		$38.2K Sell
3,750
-440
-11% -$4.54K ﹤0.01% 1317
2022
Q3 		$54K Buy
+4,190
New +$85.5K ﹤0.01% 1344
2022
Q2 		– Sell
-2,690
Closed -$101K – 1370
2022
Q1 		$101K Buy
+2,690
New +$157K ﹤0.01% 1259
2020
Q2 		– Sell
-1,750
Closed -$398K – 1368
2020
Q1 		$398K Sell
1,750
-4,250
-71% -$874K 0.01% 841
2019
Q4 		$1.48M Sell
6,000
-500
-8% -$49.8K 0.02% 638
2019
Q3 		$371K Sell
6,500
-890
-12% -$54.3K 0.01% 1045
2019
Q2 		$349K Hold
7,390
– – ﹤0.01% 1066
2019
Q1 		$398K Buy
+7,390
New +$373K 0.01% 1087
2018
Q4 		– Sell
-4,500
Closed -$264K – 1428
2018
Q3 		$264K Buy
4,500
+2,000
+80% +$118K ﹤0.01% 1276
2018
Q2 		$133K Hold
2,500
– – ﹤0.01% 1345
2018
Q1 		$704K Hold
2,500
– – 0.01% 971
2017
Q4 		$588K Hold
2,500
– – 0.01% 1040
2017
Q3 		$710K Hold
2,500
– – 0.01% 974
2017
Q2 		$704K Hold
2,500
– – 0.01% 965
2017
Q1 		$835K Hold
2,500
– – 0.01% 879
2016
Q4 		$826K Sell
2,500
-600
-19% -$161K 0.01% 891
2016
Q3 		$828K Hold
3,100
– – 0.01% 880
2016
Q2 		$410K Buy
3,100
+2,500
+417% +$397K 0.01% 1130
2016
Q1 		$106K Sell
600
-150
-20% -$29.2K ﹤0.01% 1371
2015
Q4 		$187K Hold
750
– – ﹤0.01% 1315
2015
Q3 		$211K Hold
750
– – ﹤0.01% 1295
2015
Q2 		$104K Buy
+750
New +$114K ﹤0.01% 1428

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Bridgeway Capital Management's NGNE Position: Q1 2026 in Review

Bridgeway Capital Management increased its Neurogene (NGNE) stake by 74% in Q1 2026, buying an estimated $155K and bringing the position to 18,781 shares worth $379K. The position accounts for 0.01% of the portfolio, ranked #878.

Bridgeway Capital Management first reported a position in NGNE in Q2 2015 and has held it in 26 quarters since. The position peaked at $1.48M in Q4 2019. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Bridgeway Capital Management held 18,781 shares of Neurogene worth $379K as of Q1 2026.
  • Bridgeway Capital Management bought 8,000 Neurogene shares in Q1 2026, an estimated $155K.
  • Neurogene made up 0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #878 holding.
  • Bridgeway Capital Management first reported a position in Neurogene in Q2 2015 and has held it in 26 quarters since.
  • Bridgeway Capital Management's Neurogene position peaked at $1.48M in Q4 2019.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.